Wendy St Peter

Publications (9)48.91 Total impact

• Article: 'United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States.

  Allan J Collins, Robert N Foley, Blanche Chavers, David Gilbertson, Charles Herzog, Kirsten Johansen, Bertram Kasiske, Nancy Kutner, Jiannong Liu, Wendy St Peter, [......], Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Edward Constantini, Susan Everson, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 01/2012; 59(1 Suppl 1):A7, e1-420. · 5.43 Impact Factor
• Article: US Renal Data System 2010 Annual Data Report.

  Allan J Collins, Robert N Foley, Charles Herzog, Blanche Chavers, David Gilbertson, Areef Ishani, Bertram Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean, [......], Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Edward Constantini, Susan Everson, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 01/2011; 57(1 Suppl 1):A8, e1-526. · 5.43 Impact Factor
• Article: Excerpts from the US Renal Data System 2009 Annual Data Report.

  Allan J Collins, Robert N Foley, Charles Herzog, Blanche M Chavers, David Gilbertson, Areef Ishani, Bertram L Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean, [......], Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Edward Constantini, Susan Everson, Paul W Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 01/2010; 55(1 Suppl 1):S1-420, A6-7. · 5.43 Impact Factor
• Article: United States Renal Data System 2008 Annual Data Report.

  Allan J Collins, Robert N Foley, Charles Herzog, Blanche Chavers, David Gilbertson, Areef Ishani, Bertram Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean, [......], Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Edward Constantini, Susan Everson, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 02/2009; 53(1 Suppl):S1-374. · 5.43 Impact Factor
• Article: Excerpts from the United States Renal Data System 2007 annual data report.

  Allan J Collins, Robert Foley, Charles Herzog, Blanche Chavers, David Gilbertson, Areef Ishani, Bertram Kasiske, Jiannong Liu, Lih-Wen Mau, Marshall McBean, [......], Eric Frazier, Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Edward Constantini, Susan Everson, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 02/2008; 51(1 Suppl 1):S1-320. · 5.43 Impact Factor
• Article: Excerpts from the United States Renal Data System 2006 Annual Data Report.

  Allan J Collins, Bertram Kasiske, Charles Herzog, Blanche Chavers, Robert Foley, David Gilbertson, Richard Grimm, Jiannong Liu, Thomas Louis, Willard Manning, [......], Christopher Hanzlik, Roger Johnson, Daniel Sheets, Xinyue Wang, Beth Forrest, Delaney Berrini, Edward Constantini, Susan Everson, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 02/2007; 49(1 Suppl 1):A6-7, S1-296. · 5.43 Impact Factor
• Article: Excerpts from the United States Renal Data System 2004 annual data report: atlas of end-stage renal disease in the United States.

  Allan J Collins, Bertram Kasiske, Charles Herzog, Blanche Chavers, Robert Foley, David Gilbertson, Richard Grimm, Jiannong Liu, Thomas Louis, Willard Manning, [......], Eric Frazier, Roger Johnson, Daniel Sheets, Beth Forrest, Delaney Berrini, Edward Constantini, Susan Everson, Pamela Frederick, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 02/2005; 45(1 Suppl 1):A5-7, S1-280. · 5.43 Impact Factor
• Article: Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?

  Annamaria T Kausz, Craig Solid, Brian J G Pereira, Allan J Collins, Wendy St Peter
  [show abstract] [hide abstract]
  ABSTRACT: Most incident hemodialysis (HD) patients who initiate dialysis therapy with anemia usually can achieve a hemoglobin (Hb) level of 11 g/dL or greater (> or =110 g/L) within a few months of the initiation of recombinant human erythropoietin (EPO) therapy. However, patients unable to achieve this level may be at greater risk for adverse outcomes. Whether intractable anemia is a modifiable problem or a marker for other conditions is unclear. This question was addressed in a cohort of 130,544 incident HD patients from 1996 to 2000 who were administered EPO regularly. Medicare claims data were used to determine demographic characteristics, comorbidities, hospitalizations, and related events. Patients who did not achieve an Hb level of 11 g/dL or greater (> or =110 g/L; n = 19,096; 14.6%) during months 4 to 9 after dialysis therapy initiation were compared with those who did. Patients unable to achieve an Hb level of 11 g/dL (110 g/L) were younger and more often of nonwhite race. In addition, these patients had more comorbid conditions; experienced more hospitalizations with longer stays, more infectious hospitalizations, and more catheter insertions; and were administered more blood transfusions. EPO was administered in higher and increasing doses during the years of study among patients with intractable anemia compared with those with an Hb level of 11 g/dL or greater (> or =110 g/L), likely denoting increasing attempts to correct anemia over the years. It is apparent that incident HD patients unable to achieve an Hb level of 11 g/dL or greater (> or =110 g/L) have a greater disease burden. The independent association of intractable anemia with such future outcomes as cardiovascular events and hospitalizations remains to be determined.
  American Journal of Kidney Diseases 01/2005; 45(1):136-47. · 5.43 Impact Factor
• Article: Excerpts from the United States Renal Data System 2003 Annual Data Report: atlas of end-stage renal disease in the United States.

  Allan J Collins, Bertram Kasiske, Charles Herzog, Shu-Cheng Chen, Susan Everson, Edward Constantini, Richard Grimm, Marshall McBean, Jay Xue, Blanche Chavers, [......], Craig Solid, Cheryl Arko, Frank Daniels, Xinyue Wang, Beth Forrest, David Gilbertson, Wendy St Peter, Pamela Frederick, Paul Eggers, Lawrence Agodoa
  American Journal of Kidney Diseases 01/2004; 42(6 Suppl 5):A5-7, S1-230. · 5.43 Impact Factor